| Improving trial generalizability using observational studies D Lee, S Yang, L Dong, X Wang, D Zeng, J Cai Biometrics, 2021 | 65 | 2021 |
| Doubly robust estimators for generalizing treatment effects on survival outcomes from randomized controlled trials to a target population D Lee, S Yang, X Wang Journal of causal inference 10 (1), 415-440, 2022 | 29* | 2022 |
| Transporting survival of an HIV clinical trial to the external target populations D Lee, C Gao, S Ghosh, S Yang Journal of biopharmaceutical statistics 34 (6), 922-943, 2024 | 12 | 2024 |
| Survival analysis from the INCREASE study in PH-ILD: evaluating the impact of treatment crossover on overall mortality SD Nathan, S Johri, JM Joly, CS King, A Raina, CA McEvoy, D Lee, ... thorax 79 (4), 301-306, 2024 | 10 | 2024 |
| Survival and drug persistence in patients receiving inhaled treprostinil at doses greater than 54 µg (nine breaths) four times daily S Shapiro, S Mandras, R Restrepo-Jaramillo, E Shen, M Broderick, Y Rao, ... Pulmonary Circulation 11 (4), 20458940211052228, 2021 | 6 | 2021 |
| genrct: A statistical analysis framework for generalizing RCT findings to real-world population D Lee, S Yang, M Berry, T Stinchcombe, HJ Cohen, X Wang Journal of Biopharmaceutical Statistics 34 (6), 873-892, 2024 | 4 | 2024 |
| Real‐world dosing characteristics and utilization of parenteral treprostinil in the outpatient setting VP Balasubramanian, Z Safdar, MR Sketch, M Broderick, AC Nelsen, ... Pulmonary Circulation 12 (1), e12016, 2022 | 3 | 2022 |
| Real-world transitions from parenteral, inhaled, and oral prostacyclin-class therapies to oral treprostinil: interim data from the ADAPT registry S Sahay, A Ravichandran, K Parikh, K Gordon, M Broderick, D Lee, ... B56. PULMONARY HYPERTENSION CLINICAL TRIALS ENDEAVOR SAFETY, COMBINATION …, 2020 | 3 | 2020 |
| Interim data from the ADAPT registry: real-world tolerability and management of adverse events in patients receiving oral treprostinil J Kingrey, J Swisher, A Ravichandran, J Gordon, K Gordon, M Broderick, ... Chest 158 (4), A2169-A2170, 2020 | 2 | 2020 |
| Dose-response analysis of inhaled treprostinil in pulmonary hypertension associated with interstitial lung disease and its effects on clinical worsening VF Tapson, SD Nathan, M Fisher, H Ford, J Gagermeier, J Parambil, ... Pulm. Vasc. Dis. 160 (4 Suppl), A2279-A2280, 2021 | 1 | 2021 |
| Practical management of oral treprostinil in patients with pulmonary arterial hypertension: Lessons from ADAPT, EXPEDITE, and expert consensus J Brewer, M Wilson, JC Coons, A Schmit, ME Whittenhall, A Kimber, ... Respiratory medicine 231, 107734, 2024 | | 2024 |
| ORAL TREPROSTINIL IMPROVES SURVIVAL IN FREEDOM-EV AND FREEDOM-EV OPEN-LABEL EXTENSION PARTICIPANTS WITH PULMONARY ARTERIAL HYPERTENSION RJ White, JW McConnell, AB Waxman, A Hage, LM Cadaret, ... Chest 164 (4), A5873-A5875, 2023 | | 2023 |
| Bayesian Analysis of First-Order Markov Models for Autocorrelated Binary Responses D Lee, S Ghosh Journal of Statistical Theory and Practice 17 (1), 9, 2023 | | 2023 |
| Semiparametric Inference of Randomized Controlled Trials and Observational Studies D Lee North Carolina State University, 2022 | | 2022 |
| REAL-WORLD PATIENT REPORTED OUTCOMES USING SF-12 AND EMPHASIS-10 IN PATIENTS RECEIVING ORAL TREPROSTINIL: INTERIM ANALYSIS FROM THE ADAPT REGISTRY S Sahay, A Khan, D Lachant, D Lee, C Park, M Broderick, R Benza Chest 160 (4), 2290A-2291A, 2021 | | 2021 |
